

How can you achieve



IMPACT?

“Testing simultaneously for CT, GC, and Trichomonas is optimal for detection of the most common treatable STIs in female patients.”¹

2013 IDSA & ASM Guidelines

Expand your lab’s molecular testing potential

- Workflow **efficiency** for timely patient management²
- Diagnostic **speed and accuracy** to aid in fast, appropriate treatment²
- Testing **versatility** for a wide range of patients²

Visit moleculardiagnosics.bd.com to find out how



BD MAX™ System




Elevate the standard of care Introducing BD MAX™ CT/GC/TV

- Designed to address the 3 most prevalent nonviral sexually transmitted infections (STIs) in a single assay — *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* (CT/GC/TV)
- Strong solutions to provide quality patient care and to support clinical decision accuracy and patient management
- Versatility—fully integrated on the BD MAX System

Why change?

The consequences of CT, GC, and TV can be serious; TV is the most common curable STI worldwide. Annually in the U.S., millions of new infections are estimated to occur, an amount greater than combined new cases of chlamydia, gonorrhea, and syphilis. Serious adverse reproductive health outcomes, including pregnancy complications, pelvic inflammatory disease, and an increased risk of HIV acquisition, have been linked to TV infection.⁴




*“Among women, NAAT is highly sensitive, often detecting up to 3-5 times more *T. vaginalis* infections than wet-mount microscopy, a method with poor sensitivity (51% - 65%)”⁵*

- 2015 CDC STD Treatment Guidelines

“Trichomoniasis is considered the most common curable sexually transmitted disease. In the United States, an estimated 3.7 million people have the infection, but only about 30% develop any symptoms of trichomoniasis.”⁶

Why now?

Hospitals and laboratories are faced with increasing challenges in managing workload and patient needs. Staggering cost to the U.S. healthcare system caused by the growing number of new infections demands action in the way we test for CT/GC/TV. The high incidence and overall prevalence of STIs in the general population suggest that many Americans are at substantial risk of exposure to STIs.³



Overall Performance Compared to Patient Infection Status

Gender	Specimen	<i>Chlamydia trachomatis</i>		<i>Neisseria gonorrhoeae</i>		<i>Trichomonas vaginalis</i>	
		Sens*	Spec**	Sens	Spec	Sens	Spec
Female	Vaginal Swab	99.3%	98.6%	95.5%	99.8%	96.1%	98.9%
	Endocervical Swab	98.5%	99.2%	97.7%	99.9%	93.4%	99.3%
	Urine	91.5%	99.5%	95.7%	99.7%	92.9%	99.3%
Male	Urine	96.1%	99.4%	99.1%	100%	*Sensitivity **Specificity	

Why BD? The right treatment starts with the right test. BD MAX CT/GC/TV tests for the Top 3 most prevalent nonviral STIs at 1 time, every time, from 1 patient collection. Accurate, reliable⁷ results provide clinicians with the full picture, enhancing quality patient care.

References: 1. Baron EJ et al. Clin Infect Dis. 2013;57(4):e22-e121. 2. Van Der Pol B et al. Chlamydia, gonorrhea and trichomonas combined testing using the BD MAX™ CT/GC/TV assay using genitourinary specimen types [published online ahead of print October 26, 2016]. J Clin Microbiol. doi: 10.1128/JCM.01766-16. 3. Centers for Disease Control and Prevention. <http://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf>. Accessed September 19, 2016. 4. Coleman JS et al. Obstet Gynecol Surv. 2013;68:43-50. 5. Centers for Disease Control and Prevention. <https://www.cdc.gov/std/tg2015/>. Accessed September 20, 2016. 6. Centers for Disease Control and Prevention. <http://www.cdc.gov/std/trichomonas/stdfact-trichomoniasis.htm>. Accessed September 20, 2016. 7. BD MAX CT/GC/TV Package Insert.

BD, Sparks, MD 21152-0999 USA
800.638.8663

bd.com

© 2018 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.
1-223841-US June 2018.

